These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

387 related items for PubMed ID: 15257941

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
    Pinheiro RF, de Sá Moreira E, Silva MR, Alberto FL, Chauffaille Mde L.
    Cancer Genet Cytogenet; 2008 Jun; 183(2):89-93. PubMed ID: 18503825
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A, Ades L, Baran-Marzack F, Mozziconacci MJ, Penther D, Dobbelstein S, Stamatoullas A, Récher C, Prebet T, Moulessehoul S, Fenaux P, Eclache V.
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [Abstract] [Full Text] [Related]

  • 6. Acquisition of FLT3 or N-ras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia.
    Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P, Kuo MC.
    Leukemia; 2004 Mar; 18(3):466-75. PubMed ID: 14737077
    [Abstract] [Full Text] [Related]

  • 7. Serial determination of FLT3 mutations in myelodysplastic syndrome patients at diagnosis, follow up or acute myeloid leukaemia transformation: incidence and their prognostic significance.
    Georgiou G, Karali V, Zouvelou C, Kyriakou E, Dimou M, Chrisochoou S, Greka P, Dufexis D, Vervesou E, Dimitriadou E, Efthymiou A, Petrikkos L, Dima K, Lilakos K, Panayiotidis P.
    Br J Haematol; 2006 Aug; 134(3):302-6. PubMed ID: 16787503
    [Abstract] [Full Text] [Related]

  • 8. Low frequency of FLT3 gene internal tandem duplication and activating loop mutation in therapy-related acute myelocyticleukemia and myelodysplastic syndrome.
    Au WY, Fung AT, Ma ES, Liang RH, Kwong YL.
    Cancer Genet Cytogenet; 2004 Mar; 149(2):169-72. PubMed ID: 15036894
    [Abstract] [Full Text] [Related]

  • 9. [Detection of point mutation at second tyrosine kinase domain of FLT3 gene in acute myeloid leukemia].
    Wang LH, Wang M, Zhou CL, Chen S, Zhang XW, Xing HY, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jun; 26(6):335-8. PubMed ID: 16185475
    [Abstract] [Full Text] [Related]

  • 10. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression.
    Jädersten M, Saft L, Smith A, Kulasekararaj A, Pomplun S, Göhring G, Hedlund A, Hast R, Schlegelberger B, Porwit A, Hellström-Lindberg E, Mufti GJ.
    J Clin Oncol; 2011 May 20; 29(15):1971-9. PubMed ID: 21519010
    [Abstract] [Full Text] [Related]

  • 11. [Flt-3/ITD mutation in pediatric leukemia and its clinical significance].
    Wang J, Wang T, Li S, Lin L, Gang Y.
    Ai Zheng; 2007 Jan 20; 26(1):58-63. PubMed ID: 17222369
    [Abstract] [Full Text] [Related]

  • 12. Association of the type of 5q loss with complex karyotype, clonal evolution, TP53 mutation status, and prognosis in acute myeloid leukemia and myelodysplastic syndrome.
    Volkert S, Kohlmann A, Schnittger S, Kern W, Haferlach T, Haferlach C.
    Genes Chromosomes Cancer; 2014 May 20; 53(5):402-10. PubMed ID: 24493299
    [Abstract] [Full Text] [Related]

  • 13. Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia.
    Colovic N, Tosic N, Aveic S, Djuric M, Milic N, Bumbasirevic V, Colovic M, Pavlovic S.
    Ann Hematol; 2007 Oct 20; 86(10):741-7. PubMed ID: 17579862
    [Abstract] [Full Text] [Related]

  • 14. Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype.
    Neben K, Schnittger S, Brors B, Tews B, Kokocinski F, Haferlach T, Müller J, Hahn M, Hiddemann W, Eils R, Lichter P, Schoch C.
    Oncogene; 2005 Feb 24; 24(9):1580-8. PubMed ID: 15674343
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.
    Liu TX, Becker MW, Jelinek J, Wu WS, Deng M, Mikhalkevich N, Hsu K, Bloomfield CD, Stone RM, DeAngelo DJ, Galinsky IA, Issa JP, Clarke MF, Look AT.
    Nat Med; 2007 Jan 24; 13(1):78-83. PubMed ID: 17159988
    [Abstract] [Full Text] [Related]

  • 20. Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
    Badar T, Patel KP, Thompson PA, DiNardo C, Takahashi K, Cabrero M, Borthakur G, Cortes J, Konopleva M, Kadia T, Bohannan Z, Pierce S, Jabbour EJ, Ravandi F, Daver N, Luthra R, Kantarjian H, Garcia-Manero G.
    Leuk Res; 2015 Dec 24; 39(12):1367-74. PubMed ID: 26547258
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.